Evidence map›Paper›PMID 33015868›Full record

ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2020

Predicting susceptibility to SARS-CoV-2 infection based on structural differences in ACE2 across species.

Matthew R Alexander, Clara T Schoeder, Jacquelyn A Brown, Charles D Smart, Chris Moth, John P Wikswo, John A Capra, Jens Meiler, Wenbiao Chen, Meena S Madhur

Open access · hybridAbstract read
In one paragraph

Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 56 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Little Brown Bats (Viruses · 2023
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. SARS-CoV-2 wildlife surveillance in Ontario and Québec.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2022
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Matthew R AlexanderDepartment of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Clara T SchoederCenter for Structural Biology, Vanderbilt University, Nashville, TN, USA.
Jacquelyn A BrownDepartment of Physics and Astronomy, Vanderbilt University, Nashville, TN, USA.
Charles D SmartDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
Chris MothCenter for Structural Biology, Vanderbilt University, Nashville, TN, USA.
John P WikswoDepartment of Physics and Astronomy, Vanderbilt University, Nashville, TN, USA.
John A CapraCenter for Structural Biology, Vanderbilt University, Nashville, TN, USA.
Jens MeilerCenter for Structural Biology, Vanderbilt University, Nashville, TN, USA.
Wenbiao ChenDepartment of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA.
Meena S MadhurDepartment of Medicine, Division of Cardiovascular Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Vanderbilt University · USBiology of Infection · FRVanderbilt University Medical Center · US

Funding

Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI OWEN P MCGUINNESS · 2012 to 2026
$29.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3M
Structure based design of antibodies and vaccinesU19AI117905 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SCHIEF, WILLIAM R. · 2015 to 2019
$12.0M
Harnessing human brain and liver microphysiological systems for testing therapeutics for metastatic melanomaU01TR002383 · NCATS · VANDERBILT UNIVERSITY · PI MURPHY, WILLIAM L., TAYLOR, D. LANSING · 2018 to 2022
$7.6M
Structure based design of trimer interface epitope focused universal influenza vaccinesU01AI150739 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CROWE, JAMES E · 2020 to 2024
$6.1M
Medical Scientist Training ProgramT32GM152284 · NIGMS · VANDERBILT UNIVERSITY · PI Christopher S. Williams · 2024 to 2026
$4.8M
Drug development for tuberous sclerosis complex and other pediatric epileptogenic diseases using neurovascular and cardiac microphysiological modelsUH3TR002097 · NCATS · VANDERBILT UNIVERSITY · PI ESS, KEVIN C, NEELY, MAJA DIANA · 2019 to 2021
$4.6M
Epitope-Based Design and Modified RNA Platform for Bivalent Marburgvirus VaccineR01AI141661 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI BUKREYEV, ALEXANDER, CROWE, JAMES E · 2019 to 2023
$3.9M
The Evolution of Gene Regulation and Human DiseaseR35GM127087 · NIGMS · VANDERBILT UNIVERSITY · PI John Anthony Capra · 2018 to 2026
$3.2M
Molecular Mechanisms of Postnatal Islet alpha-cell ProliferationR01DK117147 · NIDDK · VANDERBILT UNIVERSITY · PI CHEN, WENBIAO, POWERS, ALVIN C · 2019 to 2023
$3.1M
Immunophenotyping of Human Hypertension Using Single Cell Multiplex Mass Cytometry to Identify Novel Therapeutic TargetsDP2HL137166 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MADHUR, MEENAKSHI SWAMINATHAN · 2016 to 2021
$2.8M
Structural Determinants of Allosteric Modulation of Brain GPCRsR01DA046138 · NIDA · VANDERBILT UNIVERSITY · PI MEILER, JENS · 2019 to 2023
$2.0M
American Heart Association 20PRE35080177American Heart Association EIA34480023NCATS NIH HHS U01 TR002383NCATS NIH HHS UH3 TR002097NHLBI NIH HHS DP2 HL137166NHLBI NIH HHS F30 HL151069NHLBI NIH HHS F32 HL144048NHLBI NIH HHS K08 HL153786NIAID NIH HHS R01 AI141661NIAID NIH HHS U01 AI150739NIAID NIH HHS U19 AI117905NIDA NIH HHS R01 DA046138NIDDK NIH HHS P30 DK020593NIDDK NIH HHS R01 DK117147NIGMS NIH HHS R35 GM127087NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM152284NIH HHS DK117147NIH HHS DP2HL137166NIH HHS F32HL144048-01NIH HHS R01AI141661NIH HHS R35GM127087NIH HHS U01AI150739NIH HHS U01TR002383NIH HHS U19AI117905NIH HHS UH3TR002097
6 · The paper itself

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the global pandemic of coronavirus disease-2019 (COVID-19). SARS-CoV-2 is a zoonotic disease, but little is known about variations in species susceptibility that could identify potential reservoir species, animal models, and the risk to pets, wildlife, and livestock. Certain species, such as domestic cats and tigers, are susceptible to SARS-CoV-2 infection, while other species such as mice and chickens are not. Most animal species, including those in close contact with humans, have unknown susceptibility. Hence, methods to predict the infection risk of animal species are urgently needed. SARS-CoV-2 spike protein binding to angiotensin-converting enzyme 2 (ACE2) is critical for viral cell entry and infection. Here we integrate species differences in susceptibility with multiple in-depth structural analyses to identify key ACE2 amino acid positions including 30, 83, 90, 322, and 354 that distinguish susceptible from resistant species. Using differences in these residues across species, we developed a susceptibility score that predicts an elevated risk of SARS-CoV-2 infection for multiple species including horses and camels. We also demonstrate that SARS-CoV-2 is nearly optimal for binding ACE2 of humans compared to other animals, which may underlie the highly contagious transmissibility of this virus among humans. Taken together, our findings define potential ACE2 and SARS-CoV-2 residues for therapeutic targeting and identification of animal species on which to focus research and protection measures for environmental and public health.

Indexed as

Genetic Predisposition to DiseaseAmino Acid SequenceAngiotensin-Converting Enzyme 2AnimalsCamelusCOVID-19GlycosylationHorsesHumansModels, MolecularPhylogenyProtein BindingProtein Structure, TertiaryReceptors, VirusSARS-CoV-2Sequence AlignmentAngiotensin-Converting Enzyme 2Receptors, Virusangiotensin-converting enzyme 2COVID-19protein structural elementssevere acute respiratory syndrome coronavirus 2

Identifiers

PMID33015868
PMCPMC7675292
OpenAlexW3090830885

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.